Abstract
Patients with diabetes exhibit significantly altered renin-angiotensin system (RAS) control. Recently, it has been determined that hyperglycemic conditions induce an increase in angiotensin II (AT II) expression; specifically by cardiomyocytes. Altered RAS has been shown to be associated with an increase in oxidative stress and cardiac dysfunction leading to the development of cardiac hypertrophy. The transient outward potassium current (Ito) in cardiac myocytes is mainly mediated by members of the Kv subfamily of voltage gated potassium channels and has been shown to be altered in cellular localization and expression during the development of cardiac hypertrophy. However it is not clear as to how AT II affects the pore forming complex at the cell membrane and thus directly affects the Ito current. In the current study, we explored the protective effect of PPARγ ligands on cardiomyocyte Ito by preventing NADPH Oxidase activation and the ensuing ROS formation. Furthermore, short term PPARγ activation in diabetic leptin deficient db/db mice displayed improvements in the membrane association of the molecular components of Ito as well as prolonged QT interval. These findings demonstrate that PPARγ agonists have the potential to attenuate cardiomyocyte dysfunction associated with diabetes.
Keywords: Diabetes, cardiac remodeling, PPARγ; transient outward potassium channel current, Ito.
Current Pharmaceutical Design
Title:PPARγ Activation Improves the Molecular and Functional Components of Ito Remodeling by Angiotensin II
Volume: 19 Issue: 27
Author(s): Gayani Nanayakkara, Nilmini Viswaprakash, Juming Zhong, Thiruchelvan Kariharan, John Quindry and Rajesh Amin
Affiliation:
Keywords: Diabetes, cardiac remodeling, PPARγ; transient outward potassium channel current, Ito.
Abstract: Patients with diabetes exhibit significantly altered renin-angiotensin system (RAS) control. Recently, it has been determined that hyperglycemic conditions induce an increase in angiotensin II (AT II) expression; specifically by cardiomyocytes. Altered RAS has been shown to be associated with an increase in oxidative stress and cardiac dysfunction leading to the development of cardiac hypertrophy. The transient outward potassium current (Ito) in cardiac myocytes is mainly mediated by members of the Kv subfamily of voltage gated potassium channels and has been shown to be altered in cellular localization and expression during the development of cardiac hypertrophy. However it is not clear as to how AT II affects the pore forming complex at the cell membrane and thus directly affects the Ito current. In the current study, we explored the protective effect of PPARγ ligands on cardiomyocyte Ito by preventing NADPH Oxidase activation and the ensuing ROS formation. Furthermore, short term PPARγ activation in diabetic leptin deficient db/db mice displayed improvements in the membrane association of the molecular components of Ito as well as prolonged QT interval. These findings demonstrate that PPARγ agonists have the potential to attenuate cardiomyocyte dysfunction associated with diabetes.
Export Options
About this article
Cite this article as:
Nanayakkara Gayani, Viswaprakash Nilmini, Zhong Juming, Kariharan Thiruchelvan, Quindry John and Amin Rajesh, PPARγ Activation Improves the Molecular and Functional Components of Ito Remodeling by Angiotensin II, Current Pharmaceutical Design 2013; 19 (27) . https://dx.doi.org/10.2174/1381612811319270006
DOI https://dx.doi.org/10.2174/1381612811319270006 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
“Endothelial Progenitor Cells” as a Therapeutic Strategy in Cardiovascular Disease
Current Vascular Pharmacology Emerging Concepts for Myocardial Late Gadolinium Enhancement MRI
Current Cardiology Reviews Cellular Membranes and Lipid-Binding Domains as Attractive Targets for Drug Development
Current Drug Targets Recent Advances in Endocrine Metabolic Immune Disorders Drug Targeting: An Editorial Overview
Endocrine, Metabolic & Immune Disorders - Drug Targets Role of Pancreatic β-Cell Death and Cell Death-Associated Inflammation in Diabetes
Current Molecular Medicine The Role of microRNAs in Cardiovascular Disease
Current Medicinal Chemistry Modulation of Rack-1/PKCβII Signalling By Soluble AβPPα in SH-SY5Y Cells
Current Alzheimer Research Doxorubicin Loaded Dextran-coated Superparamagnetic Iron Oxide Na-noparticles with Sustained Release Property: Intracellular Uptake, Phar-macokinetics and Biodistribution Study
Current Pharmaceutical Biotechnology Animal Models Used for the Evaluation of Antiretroviral Therapies
Current HIV Research Nongenomic Actions of Thyroid Hormones: From Basic Research to Clinical Applications. An Update
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Glucocorticoid Excess Induces Accumulation of Cardiac Glycogen and Triglyceride: Suggested Role for AMPK
Current Pharmaceutical Design Toll-Like Receptors and Human Disease: Lessons from Single Nucleotide Polymorphisms
Current Genomics Mutations of Mitochondrial DNA in Atherosclerosis and Atherosclerosis-Related Diseases
Current Pharmaceutical Design Use of Contrast Echocardiography in Intensive Care and at the Emergency Room
Current Cardiology Reviews Dipeptidyl Peptidase IV Inhibitors: A New Paradigm in Type 2 Diabetes Treatment
Current Drug Targets Cardiac MRI in Autoimmune Diseases: Where Are We Now?
Current Cardiology Reviews Hypertensive Cardiomyopathy in Asymptomatic Patients: A Neglected Diagnosis
Current Hypertension Reviews Modulators of Inhibitor of Growth (ING) Family Expression in Development and Disease
Current Drug Targets The Therapeutic Potential of Hepatocyte Growth Factor for Myocardial Infarction and Heart Failure
Current Pharmaceutical Design Hypocholesterolemia
Current Vascular Pharmacology